Human medicines European public assessment report (EPAR): Blenrep, belantamab mafodotin, Date of authorisation: 23/07/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Bysumlog, insulin lispro, Date of authorisation: 06/05/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Tezspire, tezepelumab, Date of authorisation: 19/09/2022, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Vijoice, alpelisib, Date of authorisation: 15/07/2026, Status: Authorised

Orphan designation: daratumumab Treatment of AL amyloidosis, 25/05/2018 Withdrawn

Human medicines European public assessment report (EPAR): Darzalex, daratumumab, Date of authorisation: 20/05/2016, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Neofordex, dexamethasone, Date of authorisation: 16/03/2016, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 31, Status: Authorised

Medicines for human use under evaluation

Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (24 July 2026 - 20 August 2026)